Fidarestat induces glycolysis of NK cells through decreasing AKR1B10 expression to inhibit hepatocellular carcinoma

The aldose reductase inhibitor Fidarestat has been noted to have efficacy in treating a variety of tumors. To define its role in hepatocellular carcinoma (HCC), we induced a HCC xenograft model in mice, which were treated with different doses of Fidarestat. The amounts of natural killer (NK) cells a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Tiangen, Ke, Yang, Tang, Haoran, Liao, Chen, Li, Jinze, Wang, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605295/
https://www.ncbi.nlm.nih.gov/pubmed/34853813
http://dx.doi.org/10.1016/j.omto.2021.06.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605295/
https://www.ncbi.nlm.nih.gov/pubmed/34853813
http://dx.doi.org/10.1016/j.omto.2021.06.005

Ejemplares similares